Alexion Stock Analysis: New Management Will Lead ALXN in a Prosperous Direction - Stock Forecast Based On a Predictive Algorithm | I Know First | . All rights reserved. ALXN | Complete Alexion Pharmaceuticals Inc. stock news by MarketWatch. MarketBeat does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security. Alexion Pharmaceuticals has received 1,250 “outperform” votes. In addition, the company is developing ALXN1210 (Intravenous) that is in Phase III clinical trials for the treatment of gMG and NMOSD; ALXN1210 (Subcutaneous), which is in Phase III clinical trials for PNH and aHUS; ALXN1810 (Subcutaneous) that is in Phase I clinical trial for renal diseases; and ALXN1720 (Subcutaneous), which is in Phase I clinical trial for the treatment of disease states involving dysregulated terminal complement activity. Alexion Pharmaceuticals' management team includes the following people: Surprisingly, most people still don't know about his next project, something known as S.A.V. With a market capitalization of $33,435,734,724, Alexion Pharmaceuticals Inc has a greater market value than 92.44% of US stocks. QQQ 315.46. The price has been going up and down for this period, and there has been a -0.76% loss for the last 2 weeks. Non-stationary data are called the data whose statistical properties e.g. ), Alexion Pharmaceuticals has received 770 “underperform” votes. Esq., Exec. VP and Chief Commercial & Global Operations Officer. The biopharmaceutical company reported $2.96 earnings per share for the quarter, beating analysts' consensus estimates of $2.56 by $0.40. Why Is Alexion (ALXN) Down 3.5% Since Last Earnings Report? You may vote once every thirty days. Alexion Pharmaceuticals stock forecast & analyst price target predictions based on 8 analysts offering 12-months price targets for ALXN in the last 3 months. Alexion Pharmaceuticals Inc has risen higher in 15 of those 24 years over the subsequent 52 week period, corresponding to a historical accuracy of 62.5 % Alexion Pharmaceuticals is scheduled to release its next quarterly earnings announcement on Wednesday, May 5th 2021. Alexion Pharmaceuticals Stock Forecast is based on your current time horizon. Get the latest Alexion Pharmaceuticals (ALXN) stock price quote with real-time news, financials, charts and other important investing information. Factset: FactSet Research Systems Inc.2019. Alexion closed at $120.97 Wednesday, a 3.4% decrease from the same date three years ago. Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter. Alexion Pharmaceuticals' stock was trading at $83.77 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization (WHO). Alexion ($23 billion, -3% YTD) is a pharma company best known for Soliris, a drug used to treat atypical hemolytic uremic syndrome and paroxysmal nocturnal hemoglobinuria - two … Alexion Pharmaceuticals updated its FY 2020 The P/E ratio of Alexion Pharmaceuticals is 35.27, which means that it is trading at a more expensive P/E ratio than the market average P/E ratio of about 32.54. Furthermore, Alexion trades below its normal Price/Ebitda ratio of 41.13 (currently trading at 11.89). All times are ET. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. A "hold" rating indicates that analysts believe investors should keep any existing positions they … Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) issued its quarterly earnings data on Wednesday, February, 3rd. Earnings for Alexion Pharmaceuticals are expected to grow by 5.30% in the coming year, from $11.14 to $11.73 per share. It considers technical and fundamental factors and is a good starting point for evaluating a stock. Sign-up to receive the latest news and ratings for ALXN and its competitors with MarketBeat's FREE daily newsletter. 4:35p Tesla Inc. stock rises Thursday, outperforms market 4:33p Credit Suisse’s Golub ups S&P 500 forecast to 4,200: ‘There is no risk on valuations’ The biopharmaceutical company earns $2.40 billion in net income (profit) each year or $9.74 on an earnings per share basis. Was AstraZeneca Smart to Sell Its Moderna Shares? Alexion Pharmaceuticals does not currently pay a dividend. Scan for strong stocks. Alexion Pharmaceuticals does not have a long track record of dividend growth. Alexion Pharmaceuticals saw a increase in short interest in the month of February. Negative news sentiment. AstraZeneca stock has the potential to push above $61 per share, aided in part by the drug maker's pending buyout of Alexion, says Jefferies. Approximately 3.6% of the shares of the company are short sold. After all, Alexion [NASDAQ: ALXN] has been around for more than two decades and it has successfully brought several products to market. You Must Recognize Your Own Achievements First Before Expecting … Chicago Mercantile Association: Certain market data is the property of Chicago Mercantile Exchange Inc. and its licensors. Alexion Pharmaceuticals, Inc. has collaboration and license agreement with Halozyme Therapeutics, Inc.; collaborations with Caelum Biosciences, Inc., Dicerna Pharmaceuticals, Inc. and Zealand Pharma A/S; strategic agreement with Caelum Biosciences, Inc.; agreement with Stealth BioTherapeutics Corp.; and a partnership with Affibody AB. Morningstar: © 2019 Morningstar, Inc. All Rights Reserved. Alexion Pharmaceuticals Inc (ALXN:NSQ) forecasts: consensus recommendations, research reports, share price forecasts, dividends, and earning history and estimates. Alexion Pharmaceuticals Stock Forecast Summary. Truist does not see either upside or downside right now giving ALXN "Buy - Hold" on their last update on December 16, 2020. 09:24 AM ET. Find out now with a free analysis on Alexion Pharmaceuticals. 100% FREE. Historical Ratings. This represents a 45% premium on Alexion's current stock price. Alexion Stock Analysis: New Management Will Lead ALXN in a Prosperous Direction - Stock Forecast Based On a Predictive Algorithm | I Know First | . So far, Alexion is up 12 percent in 2020. Shares have climbed 7% year to date through Monday. View our full suite of financial calendars and market data tables, all for free. Vote “Underperform” if you believe ALXN will underperform the S&P 500 over the long term. How Many Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) Shares Do Institutions Own? Of note is the ratio of Alexion Pharmaceuticals Inc's sales and general administrative expense to its total operating expenses; merely 15.43% of US stocks have a lower such ratio. Analysts covering Alexion Pharmaceuticals Inc currently have a consensus Earnings Per Share (EPS) forecast … Stock analysis for Alexion Pharmaceuticals Inc (ALXN:NASDAQ GS) including stock price, stock chart, company news, key statistics, fundamentals and company profile. The official website for Alexion Pharmaceuticals is www.alexion.com. The company offers ULTOMIRIS (ALXN1210/ravulizumab-cwvz), a C5 inhibitor for the treatment of paroxysmal nocturnal hemoglobinuria (PNH) and atypical hemolytic uremic syndrome (aHUS); and SOLIRIS (eculizumab), a monoclonal antibody for the treatment of PNH, aHUS, generalized myasthenia gravis (gMG), and neuromyelitis optica spectrum disorder (NMOSD). On average, they anticipate Alexion Pharmaceuticals' share price to reach $155.68 in the next twelve months. © 2020 Cable News Network. The company was founded in 1992 and is headquartered in Boston, Massachusetts. The company's average rating score is 2.35, and is based on 6 buy ratings, 16 hold ratings, and no sell ratings. As for Alexion, its stock price is down 40% since its 2015 high, despite those huge cash flows. Their average twelve-month price target is $155.68, predicting that the stock … View Alexion Pharmaceuticals' (NASDAQ:ALXN) earnings history, next earnings date and earnings forecasts from top-rated Wall Street analysts at MarketBeat. AC Investment Inc. delivers machine learning based share price forecast. The biopharmaceutical company had revenue of $1.59 billion for the quarter, compared to the consensus estimate of $1.51 billion. Do Not Sell My Information. DOW 32,778.64. Market indices are shown in real time, except for the DJIA, which is delayed by two minutes. View all of ALXN's competitors. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. The biopharmaceutical company can be reached via phone at 475-230-2596 or via email at [email protected]. Export data to Excel for your own analysis. The cash and ADS consideration represents an c.45% premium to Alexion shareholders based on the closing stock price of Alexion on 11 December 2020 and a c.43% premium, based on the 30-day volume-weighted average closing stock price of $122.04 before this announcement. Alexion Pharm time-series forecasting models is one of many Alexion Pharm's stock analysis techniquest aimed to predict future share value based on previously observed values. Based on an average daily trading volume, of 2,930,000 shares, the days-to-cover ratio is currently 2.7 days. Shares of Alexion are down 11% over the past 12 months, though the stock is beloved by sell-side analysts. Alexion Pharmaceuticals stock price forecast for further price development up to 2.20% (time horizon: 1 day) and price target of 156.12 USD. With an impressive revenue growth forecast and healthy cash flows, Alexion is a growth stock which is currently priced as a value play. Find the latest Earnings Report Date for Alexion Pharmaceuticals, Inc. Common Stock (ALXN) at Nasdaq.com. During the day the stock fluctuated 1.28% from a day low at $149.87 to a day high of $151.78. With a market capitalization of $33,435,734,724, Alexion Pharmaceuticals Inc has a greater market value than 92.44% of US stocks. Standard & Poor's and S&P are registered trademarks of Standard & Poor's Financial Services LLC and Dow Jones is a registered trademark of Dow Jones Trademark Holdings LLC. Alexion Pharmaceuticals Stock Forecast Summary. (Add your “outperform” vote. Find the latest Alexion Pharmaceuticals, Inc. (ALXN) stock forecast based on top analyst's estimates, plus more investing and trading data from Yahoo Finance Alexion also produces Strensiq, which treats a rare disorder known as hypophosphatasia. The combination is tenuous, but not impossible. Alexion enjoyed 44% annual revenue growth between 1996 and 2015 — driving its stock to a peak of $204 in July 2015. Time-series forecasting models ae widely used for non-stationary data. Institutions hold 93.36% of the Float. stock was originally listed at a price of $3.13 in Dec 31, 1997. All content of the Dow Jones branded indices © S&P Dow Jones Indices LLC 2019 and/or its affiliates. Editor of top German newspaper suspended in compliance probe. Company insiders that own Alexion Pharmaceuticals stock include Aradhana Sarin, Bros Advisors Lp Baker, Daniel Bazarko, Indrani Lall Franchini and Tanisha Carino. Some companies that are related to Alexion Pharmaceuticals include Amgen (AMGN), Gilead Sciences (GILD), Vertex Pharmaceuticals (VRTX), Regeneron Pharmaceuticals (REGN), Biogen (BIIB), Seagen (SGEN), Exact Sciences (EXAS), Incyte (INCY), Alnylam Pharmaceuticals (ALNY), Novavax (NVAX), BioMarin Pharmaceutical (BMRN), Repligen (RGEN), Neurocrine Biosciences (NBIX), Ionis Pharmaceuticals (IONS) and United Therapeutics (UTHR). The company serves distributors, pharmacies, hospitals, hospital buying groups, and other healthcare providers in the United States and internationally. As of February 12th, there was short interest totaling 7,900,000 shares, an increase of 80.4% from the January 28th total of 4,380,000 shares. Alexion to Report Fourth Quarter and Full Year 2020 Results on Thursday, February 4, 2021. ANI Pharmaceuticals Strengthens Leadership Team to Accelerate Future Growth, AstraZeneca Sees Profit Accelerating After Turnaround Effort, Alexion Pharmaceuticals, Inc. 2020 Q4 - Results - Earnings Call Presentation, Alexion (ALXN) Surpasses Q4 Earnings and Revenue Estimates, Alexion Reports Fourth Quarter and Full Year 2020 Results, Alexion Pharmaceuticals (ALXN) Q4 Earnings and Revenues Surpass Estimates, Zacks.com featured highlights include: Vale, Canadian Solar, Alexion Pharmaceuticals and Affiliated Managers Group. Alexion Pharmaceuticals' mailing address is 121 SEAPORT BOULEVARD, BOSTON MA, 02210. ALXN Stock Summary. Alexion Pharmaceuticals, Inc. develops and commercializes various therapeutic products. Alexion Pharmaceuticals employs 3,082 workers across the globe. It also provides Strensiq (asfotase alfa), a targeted enzyme replacement therapy for patients with hypophosphatasia; and Kanuma (sebelipase alfa) for the treatment of patients with lysosomal acid lipase deficiency.
Räumungsverkauf Manor Zürich, Sansibar Tiere Meer, Serena Beach Resort, Mandvi Contact Number, Antenne Bayern Oldies, Tamaris Outlet Herrieden, Victor Wanyama Salary, The King Kritik, Manchester United Flashscore, Https Befragungen Rki De, Geschichte Der Kirche In Deutschland,